Key result
Angiotensin II effectively manages hypotension during percutaneous hepatic perfusion, suggesting viability in vasodilatory shock.
Why the study?
Intraoperative management during percutaneous hepatic perfusion is complicated by profound vasoplegia requiring maximal vasopressors, and literature supporting the hypothesized catecholamine-filtration mechanism is limited.
Does angiotensin II improve hypotension management in patients experiencing vasodilatory shock during percutaneous hepatic perfusion?
Does angiotensin II improve hypotension management in patients experiencing vasodilatory shock during percutaneous hepatic perfusion?
Angiotensin II may be an effective alternative for managing profound vasoplegia during percutaneous hepatic perfusion.
Should not yet change vasopressor practice; leaves open angiotensin II as option for procedural vasodilatory shock.
Percutaneous hepatic perfusion (PHP) is an effective treatment for isolated liver metastases from uveal melanoma. Intraoperative anesthetic management is challenging due to extreme hemodynamic fluctuations associated with the venovenous bypass circuit, hemofiltration system, and hepatic artery chemotherapy delivery. Patients often require maximal doses of multiple vasopressors to maintain adequate perfusion. The mechanism of intraoperative hypotension is hypothesized to be due to catecholamine filtration, though literature supporting this mechanism is limited. The following report describes the successful use of angiotensin II for hypotension management during a PHP procedure, supporting the potential for an alternative mechanism for this profound vasoplegia.
No takes yet. Share an insight, caveat, or question.
Andrew et al. (2026) studied this question. Angiotensin II effectively managed hypotension during percutaneous hepatic perfusion procedures, suggesting it may be a viable treatment for vasodilatory shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: